MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$98,509K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-05-31
2026-02-28
2025-11-30
2025-08-31
Net loss
-89,535
-87,174
-78,221
-186,236
Depreciation and amortization
2,255
2,196
2,120
6,620
Stock-based compensation
11,388
9,404
9,086
28,879
Net accretion of discount on marketable securities
1,557
1,978
1,867
8,455
Loss on disposal of property and equipment
0
-160
-89
-
Amortization of operating lease right-of-use assets
1,595
1,580
2,511
7,605
Other
-
-
0
0
Accounts receivable
0
-
-
-
Prepaid expenses and other assets
-263
-1,287
1,284
4,945
Accounts payable
1,872
-461
3,025
-3,655
Deferred revenue
-7,044
-1,252
-13,577
-23,403
Operating lease liabilities
-557
205
-756
-4,311
Accrued expenses and other current liabilities
-15,253
4,119
11,042
6,268
Net cash used in operating activities
-96,573
-71,914
-67,832
-181,633
Purchases of marketable securities
24,628
255,934
174,338
281,350
Maturities of marketable securities
119,561
133,153
179,815
437,728
Purchases of property and equipment
1,936
1,045
5,131
8,871
Net cash provided by (used in) investing activities
92,997
-123,826
346
147,507
Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs
-
-
234,762
0
Proceeds from exercise of stock options and pre-funded warrants
-
-
1,651
-
Proceeds from exercise of stock options
66
-30
-
405
Proceeds from issuance of common stock under employee stock purchase plan
0
1,596
0
2,229
Proceeds from issuances of common stock in at the market financing, net of issuance costs
0
18,004
0
0
Repurchase of unvested early exercised stock options
-
-
0
0
Net cash provided by financing activities
66
19,975
236,008
2,634
Net decrease in cash, cash equivalents and restricted cash
-3,510
-175,765
168,522
-31,492
Cash and cash equivalents at beginning of period
-
-
110,898
-
Cash, cash equivalents and restricted cash at beginning of period
79,406
79,406
-
110,898
Cash and cash equivalents at end of period
-
-
247,928
-
Cash, cash equivalents and restricted cash at end of period
68,653
72,163
-
79,406
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$119,561K
Proceeds from exercise of
stock options
$66K
Net cash provided by
(used in) investing...
$92,997K
Net cash provided by
financing activities
$66K
Canceled cashflow
$26,564K
Net decrease in
cash, cash...
-$3,510K
Canceled cashflow
$93,063K
Stock-based compensation
$11,388K
Depreciation and
amortization
$2,255K
Accounts payable
$1,872K
Amortization of operating
lease right-of-use...
$1,595K
Prepaid expenses and
other assets
-$263K
Purchases of marketable
securities
$24,628K
Purchases of property and
equipment
$1,936K
Net cash used in
operating activities
-$96,573K
Canceled cashflow
$17,373K
Net loss
-$89,535K
Accrued expenses and
other current...
-$15,253K
Deferred revenue
-$7,044K
Net accretion of
discount on marketable...
$1,557K
Operating lease
liabilities
-$557K
Buy us a coffee
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)